Back to Krebs Biochemicals and Industries

Krebs Biochemicals and Industries — Peer Comparison

How the peer fair value is calculated and which companies were used as benchmarks.

Peer selection

Peers are selected from the same Healthcare industry. 8 companies were matched as valid comparables.

Same-industry peers share similar business models, cost structures, and growth prospects — making them the most appropriate benchmarks for valuation multiples.

Peer comparison table

Healthcare · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
Krebs Biochemicals and Industries KREBSBIO · you	₹111 Cr	—	—	—	10.4%	-71.3%	-23.1%
Sector median	—	35.4×	2.8×	16.0×	6.3%	1.9%	8.3%
Laxmi Dental Limited LAXMIDENTL	₹1,099 Cr	39.2×	4.7×	26.4×	11.9%	10.4%	19.8%
Sigachi Industries Limited SIGACHI	₹1,041 Cr	40.0×	2.3×	—	5.8%	0.1%	—
Health X Platform Limited HEALTHX	₹954 Cr	796.5×	1.5×	—	0.2%	0.1%	8.3%
Bharat Parenterals Limited BPLPHARMA	₹930 Cr	96.0×	2.9×	—	3.0%	0.1%	—
Wanbury Limited WANBURY	₹915 Cr	16.4×	23.6×	—	144.2%	0.0%	—
Kopran Limited KOPRAN	₹893 Cr	34.0×	1.6×	13.4×	4.8%	3.8%	7.3%
Anlon Healthcare Limited AHCL	₹846 Cr	23.3×	3.3×	18.6×	12.6%	16.9%	15.1%
Amanta Healthcare Limited AMANTA	₹696 Cr	35.4×	2.7×	13.4×	6.8%	5.2%	3.5%

Peer comparison verdict

Krebs is fairly valued relative to sector peers — trading near the sector median on key multiples (P/E ~35.4×, EV/EBITDA ~16.0×). Focus on execution quality and earnings trajectory from here.

Why median? Why these weights?

Median over mean: The sector median is used instead of the average because valuation multiples have extreme outliers — one high-growth company at 200× P/E would dramatically skew a mean. The median gives the middle value in the peer set, which better represents typical pricing.

Sector-specific weights: The weight given to each method reflects what matters most in this sector. For banks, P/B dominates because their value is tied to book assets. For IT companies, P/E carries the most weight because earnings quality matters more than asset base. For capital-intensive businesses, EV/EBITDA accounts for varying debt levels across peers and removes financing structure bias.

Limitations of peer comparison

Peer comparison assumes comparable companies are truly comparable — which is never perfectly true. Sector classifications can be imperfect: a conglomerate classified as "IT" may also have significant manufacturing revenue. Small peer counts (below 5) reduce confidence, as a single outlier can skew the sector median. When the entire sector is broadly expensive, peer comparison will show even an expensive stock as "fairly valued" relative to its peers.

The peer fair value shown is an algorithmic estimate based on publicly available financial data. It is not investment advice or a recommendation to buy, sell, or hold any security. Please consult a SEBI-registered investment adviser before making any investment decision.